Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative..

JAMA Neurol. 2013 Oct;70(10):1277-87.

2.

Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D.

J Parkinsons Dis. 2015;5(4):783-92. doi: 10.3233/JPD-150682.

3.

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.

Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J.

Acta Neuropathol. 2013 Nov;126(5):683-97. doi: 10.1007/s00401-013-1148-z. Epub 2013 Jun 29.

4.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

PMID:
25971633
5.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative..

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

PMID:
27021906
6.

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.

Brockmann K, Schulte C, Deuschle C, Hauser AK, Heger T, Gasser T, Maetzler W, Berg D.

Parkinsonism Relat Disord. 2015 Dec;21(12):1427-34. doi: 10.1016/j.parkreldis.2015.10.008. Epub 2015 Oct 14.

PMID:
26475624
7.

CSF biomarkers and clinical progression of Parkinson disease.

Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O.

Neurology. 2015 Jan 6;84(1):57-63. doi: 10.1212/WNL.0000000000001098. Epub 2014 Nov 19.

8.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM.

Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.

9.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.

JAMA Neurol. 2015 Oct;72(10):1175-82. doi: 10.1001/jamaneurol.2015.1449.

PMID:
26258692
10.

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J.

Ann Neurol. 2011 Mar;69(3):570-80. doi: 10.1002/ana.22311. Epub 2011 Mar 11.

11.

Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.

Rochester L, Galna B, Lord S, Yarnall AJ, Morris R, Duncan G, Khoo TK, Mollenhauer B, Burn DJ.

Neurology. 2017 Apr 18;88(16):1501-1511. doi: 10.1212/WNL.0000000000003840. Epub 2017 Mar 22.

12.

Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.

Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT.

Neurobiol Aging. 2015 Jan;36(1):476-84. doi: 10.1016/j.neurobiolaging.2014.07.043. Epub 2014 Aug 4.

13.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

PMID:
21469206
14.

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6. doi: 10.1136/jnnp.2009.199950. Epub 2010 Jun 14.

PMID:
20547614
15.

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.

Terrelonge M Jr, Marder KS, Weintraub D, Alcalay RN.

J Mol Neurosci. 2016 Jan;58(1):88-92. doi: 10.1007/s12031-015-0647-x. Epub 2015 Sep 2.

16.

Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.

Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, De Deyn PP, Engelborghs S.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S290-8. doi: 10.1016/j.jalz.2013.10.004. Epub 2014 Jan 15.

PMID:
24439167
17.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
18.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B.

PLoS One. 2016 Apr 26;11(4):e0153564. doi: 10.1371/journal.pone.0153564. eCollection 2016.

19.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.

Arch Neurol. 2012 Nov;69(11):1445-52.

PMID:
22925882
20.

An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.

Sun Y, Bresell A, Rantalainen M, Höglund K, Lebouvier T, Salter H; Alzheimer Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;45(4):1061-76. doi: 10.3233/JAD-142118.

PMID:
25720397

Supplemental Content

Support Center